Viridian Therapeutics, Inc.\DE (VRDN) shareholders
Close on Nov 18, 2026Market cap $3.41BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Fairmount Funds Management LLC Joint filing with Fairmount Healthcare Fund II GP LLC (14.04%) | 17,201,800 | 14.04% | 13D (active) amendment | May 11, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (14.50%) | 7,625,542 | 14.50% | 13G (passive) | Jan 10, 2024 |
| Bellevue Asset Management AG Joint filing with Bellevue Group AG (6.60%) | 6,726,144 | 6.60% | 13G (passive) | Mar 31, 2026 |
| Paradigm BioCapital Advisors LP Joint filing with Paradigm BioCapital Advisors GP LLC (6.10%), Senai Asefaw, M.D. (6.10%) and 1 more | 6,723,788 | 6.10% | 13G (passive) amendment | Jun 30, 2026 |
| T. Rowe Price Associates, Inc. | 5,748,426 | 5.20% | 13G (passive) | Jun 30, 2026 |
| Point72 Capital Advisors, Inc. Joint filing with Point72 Asset Management, L.P. (5.00%), Steven A. Cohen (5.00%) | 5,687,507 | 5.00% | 13G (passive) | Aug 19, 2026 |
| BlackRock, Inc. | 3,426,450 | 6.50% | 13G (passive) amendment | Dec 31, 2023 |
| Kynam Capital Management, LP Joint filing with Kynam Capital Management GP, LLC (5.76%), Yue Tang (5.76%) | 0 | 5.76% | 13G (passive) | Mar 31, 2025 |
| Kynam Capital Management GP, LLC Joint filing with Kynam Capital Management, LP (5.70%), Yue Tang (5.70%) | 0 | 5.70% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of VRDN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 16,604,740 | 14.66% | $305.03M | +1,225,363 | 0.01% |
| BlackRock, Inc. | 8,551,488 | 7.55% | $157.09M | +720,013 | 0.00% |
| Bellevue Group AG | 6,731,909 | 5.94% | $123.67M | +5,765 | 2.60% |
| Paradigm Biocapital Advisors LP | 6,723,788 | 5.93% | $123.52M | +3,574,895 | 2.31% |
| Kynam Capital Management, LP | 6,453,877 | 5.70% | $118.56M | +4,112,225 | 6.55% |
| State Street Corp | 6,124,976 | 5.41% | $112.52M | +1,452,091 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 5,748,410 | 5.07% | $105.60M | +2,542,375 | 0.01% |
| Fairmount Funds Management LLC | 5,090,928 | 4.49% | $93.52M | +1,176,470 | 6.18% |
| Vanguard Capital Management LLC | 4,576,860 | 4.04% | $84.08M | +409,659 | 0.00% |
| Deep Track Capital, LP | 3,592,740 | 3.17% | $66.00M | +2,198,796 | 0.96% |
| VR Adviser, LLC | 3,257,917 | 2.88% | $59.85M | −624,792 | 1.81% |
| Wellington Management Group Llp | 3,128,362 | 2.76% | $57.47M | +49,808 | 0.01% |
| Vanguard Portfolio Management LLC | 2,752,827 | 2.43% | $50.57M | +1,111,350 | 0.00% |
| Geode Capital Management, LLC | 2,501,869 | 2.21% | $45.97M | +168,656 | 0.00% |
| Avoro Capital Advisors LLC | 2,500,000 | 2.21% | $45.93M | +1,000,000 | 0.41% |
| Baker Bros. Advisors LP | 2,383,025 | 2.10% | $43.78M | +411,347 | 0.22% |
| Point72 Asset Management, L.P. | 2,343,208 | 2.07% | $43.04M | +2,020,372 | 0.05% |
| Caligan Partners LP | 2,193,981 | 1.94% | $40.30M | New | 1.90% |
| Novo Holdings A/S | 2,135,000 | 1.88% | $39.22M | +135,000 | 2.28% |
| Tang Capital Management LLC | 1,792,626 | 1.58% | $32.93M | – | 1.50% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 214 | 136M | 100.0% | 47 / 96 | 50 / 55 | 39M | 16M |
| Q1 2026 | 225 | 112M | 99.2% | 49 / 80 | 67 / 50 | 28M | 17M |
| Q4 2025 | 229 | 108M | 95.2% | 77 / 85 | 45 / 15 | 32M | 18M |
| Q3 2025 | 169 | 94M | 82.5% | 17 / 53 | 65 / 18 | 5M | 7M |
| Q2 2025 | 170 | 95M | 83.8% | 22 / 61 | 65 / 28 | 10M | 7M |
| Q1 2025 | 176 | 91M | 80.7% | 26 / 68 | 54 / 27 | 10M | 9M |
| Q4 2024 | 178 | 91M | 80.4% | 42 / 79 | 42 / 24 | 15M | 11M |
| Q3 2024 | 165 | 88M | 77.3% | 45 / 65 | 41 / 16 | 29M | 7M |
| Q2 2024 | 138 | 70M | 61.6% | 20 / 70 | 28 / 16 | 11M | 13M |
| Q1 2024 | 136 | 72M | 64.0% | 23 / 64 | 34 / 19 | 17M | 5M |
| Q4 2023 | 132 | 61M | 53.6% | 25 / 49 | 43 / 16 | 21M | 10M |
| Q3 2023 | 123 | 50M | 44.3% | 14 / 55 | 36 / 18 | 8M | 4M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
257 funds held VRDN in Q2 2026, 34% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of VRDN | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 3,923,620 | 3.46% | $72.08M | 0.67% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 3,336,970 | 2.95% | $61.30M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,348,604 | 2.07% | $43.14M | 0.05% | Jun 30, 2026 |
| Fidelity Advisor Biotechnology Fund | 1,782,464 | 1.57% | $33.72M | 1.53% | Jul 31, 2026 |
| Select Health Care Portfolio | 1,500,000 | 1.32% | $26.43M | 0.46% | May 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1,447,742 | 1.28% | $26.60M | 0.22% | Jun 30, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 1,386,319 | 1.22% | $24.43M | 0.01% | May 31, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1,351,696 | 1.19% | $24.83M | 0.17% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 1,308,304 | 1.15% | $23.05M | 0.44% | May 31, 2026 |
| Fidelity Small Cap Growth Fund | 1,268,990 | 1.12% | $24.01M | 0.27% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 1,130,424 | 1.00% | $20.77M | 0.02% | Jun 30, 2026 |
| Fidelity Stock Selector Small Cap Fund | 1,089,196 | 0.96% | $20.61M | 0.28% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 987,199 | 0.87% | $18.68M | 0.05% | Jul 31, 2026 |
| Vanguard Explorer Fund | 960,500 | 0.85% | $18.17M | 0.08% | Jul 31, 2026 |
| Fidelity Series Small Cap Opportunities Fund | 791,842 | 0.70% | $14.98M | 0.32% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Stephen F. Mahoney | President and CEO, Director | 33,349 | 0.03% | Mar 9, 2026 |
| Jennifer Tousignant | Chief Legal Officer | 0 | – | Aug 20, 2026 |
| Radhika Tripuraneni | Chief Medical Officer | 40,000 | 0.04% | Aug 18, 2026 |
| Seth Harmon | Chief Financial Officer | 7,850 | 0.01% | Mar 9, 2026 |
| Thomas W. Beetham | Chief Operating Officer | 13,361 | 0.01% | Mar 9, 2026 |
| Jennifer K. Moses | Director | – | – | Jul 2, 2026 |
| Sarah Gheuens | Director | – | – | Jul 2, 2026 |
| Jeffrey Robert Ajer | Director | – | – | Jul 2, 2026 |
| Tomas Kiselak | Director | – | – | Jul 2, 2026 |
| Arlene Morris | Director | – | – | Jul 2, 2026 |
| Christopher W. Cain | Director | – | – | Jul 2, 2026 |
| Funds Management LLC Fairmount | Director, 10% owner | 3,459,913 | 3.05% | May 13, 2026 |
| Healthcare Fund II GP LLC Fairmount | Director, 10% owner | 3,914,458 | 3.46% | May 13, 2026 |
| Healthcare Fund II L.P. Fairmount | Director, 10% owner | 5,090,928 | 4.49% | May 13, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jennifer Tousignant Chief Legal Officer | Aug 19, 2026 | Sale | −4,212 | $24.50 | $103.19K | 0 |
| Jennifer Tousignant Chief Legal Officer | Aug 19, 2026 | Option exercise | +10,000 | $14.41 | $144.10K | 10,000 |
| Jennifer Tousignant Chief Legal Officer | Aug 19, 2026 | Sale | −10,000 | $24.50 | $245.00K | 0 |
| Radhika Tripuraneni Chief Medical Officer | Aug 14, 2026 | Option exercise | +40,000 | $13.21 | $528.40K | 40,000 |
| Healthcare Fund II L.P. Fairmount Director, 10% owner | May 11, 2026 | Buy | +1,176,470 | $17.00 | $20.00M | 5,090,928 |
| Seth Harmon Chief Financial Officer | Mar 3, 2026 | Tax withholding | −2,031 | $30.19 | $61.32K | 7,850 |
| Thomas W. Beetham Chief Operating Officer | Mar 3, 2026 | Tax withholding | −3,048 | $30.19 | $92.02K | 13,361 |
| Jennifer Tousignant Chief Legal Officer | Mar 3, 2026 | Tax withholding | −1,675 | $30.19 | $50.57K | 3,494 |
| Stephen F. Mahoney President and CEO, Director | Mar 3, 2026 | Tax withholding | −7,408 | $30.19 | $223.65K | 33,349 |
| Thomas W. Beetham Chief Operating Officer | Mar 3, 2026 | Tax withholding | −3,138 | $29.32 | $92.01K | 13,271 |
| Thomas W. Beetham Chief Operating Officer | Mar 3, 2026 | Option exercise | +9,409 | – | – | 16,409 |
| Stephen F. Mahoney President and CEO | Mar 3, 2026 | Option exercise | +18,357 | – | – | 40,757 |
| Stephen F. Mahoney President and CEO | Mar 3, 2026 | Tax withholding | −7,627 | $29.32 | $223.62K | 33,130 |
| Seth Harmon Chief Financial Officer | Mar 3, 2026 | Tax withholding | −2,091 | $29.32 | $61.31K | 7,790 |
| Seth Harmon Chief Financial Officer | Mar 3, 2026 | Option exercise | +6,267 | – | – | 9,881 |
| Jennifer Tousignant Chief Legal Officer | Mar 3, 2026 | Tax withholding | −1,724 | $29.32 | $50.55K | 3,445 |
| Jennifer Tousignant Chief Legal Officer | Mar 3, 2026 | Option exercise | +5,169 | – | – | 5,169 |
| Jennifer Tousignant Chief Legal Officer | Dec 31, 2025 | Sale | −2,272 | $31.16 | $70.80K | 0 |
| Healthcare Fund II GP LLC Fairmount Director, 10% owner | Oct 23, 2025 | Buy | +454,545 | $22.00 | $10.00M | 3,914,458 |
| Funds Management LLC Fairmount Director, 10% owner | Jun 10, 2025 | Option exercise | +12,500 | $12.31 | $153.88K | 3,459,913 |
| Funds Management LLC Fairmount Director, 10% owner | Jun 9, 2025 | Option exercise | +1,600 | $7.80 | $12.48K | 3,447,413 |
| Stephen F. Mahoney President and CEO, Director | Sep 27, 2024 | Buy | +21,400 | $23.33 | $499.26K | 21,400 |
| Thomas W. Beetham Chief Operating Officer | Sep 27, 2024 | Buy | +5,000 | $23.41 | $117.05K | 6,000 |
| Healthcare Fund II L.P. Fairmount Director, 10% owner | Sep 13, 2024 | Buy | +1,600,000 | $18.75 | $30.00M | 3,445,813 |
| Healthcare Fund II L.P. Fairmount Director, 10% owner | Mar 28, 2024 | Other | +5,859 | – | – | 1,845,813 |
| Healthcare Fund II L.P. Fairmount Director, 10% owner | Mar 28, 2024 | Other | −5,859 | – | – | 0 |
| Healthcare Fund II L.P. Fairmount Director, 10% owner | Jan 22, 2024 | Buy | +476,190 | $21.00 | $10.00M | 1,839,954 |
| Lara Meisner Chief Legal Officer | Jun 16, 2023 | Option exercise | +27 | $23.03 | $622 | 29,998 |
| Lara Meisner Chief Legal Officer | Jun 16, 2023 | Sale(10b5-1 plan) | −27 | $28.35 | $765 | 29,971 |
| Lara Meisner Chief Legal Officer | Jun 15, 2023 | Option exercise | +2,269 | $23.03 | $52.26K | 32,240 |
| Lara Meisner Chief Legal Officer | Jun 15, 2023 | Sale(10b5-1 plan) | −2,269 | $28.02 | $63.58K | 29,971 |
| Lara Meisner Chief Legal Officer | Jun 6, 2023 | Option exercise | +5,126 | $18.51 | $94.88K | 35,097 |
| Lara Meisner Chief Legal Officer | Jun 6, 2023 | Sale(10b5-1 plan) | −5,126 | $25.02 | $128.25K | 29,971 |
| Lara Meisner Chief Legal Officer | Jun 5, 2023 | Option exercise | +499 | $18.51 | $9.24K | 30,470 |
| Lara Meisner Chief Legal Officer | Jun 5, 2023 | Sale(10b5-1 plan) | −499 | $25.03 | $12.49K | 29,971 |
| Lara Meisner Chief Legal Officer | Jun 2, 2023 | Sale(10b5-1 plan) | −1,875 | $24.21 | $45.39K | 29,971 |
| Lara Meisner Chief Legal Officer | Jun 2, 2023 | Option exercise | +1,875 | $14.00 | $26.25K | 31,846 |
| Scott Dunseth Myers Chief Executive Officer, Director | Apr 12, 2023 | Buy | +4,000 | $25.37 | $101.48K | 259,500 |
| Scott Dunseth Myers Chief Executive Officer, Director | Mar 13, 2023 | Buy | +5,500 | $29.15 | $160.33K | 255,500 |
| Lara Meisner General Counsel and Secretary | Mar 9, 2023 | Sale(10b5-1 plan) | −29,971 | $29.07 | $871.26K | 0 |
| Scott Dunseth Myers Chief Executive Officer, Director | Feb 6, 2023 | Award | +250,000 | – | – | 250,000 |
| Jonathan Violin Chief Executive Officer, Director | Feb 2, 2023 | Option exercise | +50,000 | $0.15 | $7.50K | 530,905 |
| Jonathan Violin Chief Executive Officer, Director | Feb 2, 2023 | Sale(10b5-1 plan) | −50,000 | $36.80 | $1.84M | 480,905 |
| Jonathan Violin Chief Executive Officer, Director | Feb 2, 2023 | Sale(10b5-1 plan) | −50,000 | $36.80 | $1.84M | 430,905 |
| Lara Meisner General Counsel and Secretary | Jan 23, 2023 | Option exercise | +1,872 | $14.00 | $26.21K | 6,843 |
| Lara Meisner General Counsel and Secretary | Jan 23, 2023 | Sale(10b5-1 plan) | −6,843 | $35.66 | $244.02K | 0 |
| Lara Meisner General Counsel and Secretary | Jan 23, 2023 | Option exercise | +4,971 | $23.03 | $114.48K | 4,971 |
| Barrett Katz Chief Medical Officer | Jan 17, 2023 | Sale(10b5-1 plan) | −24,853 | $37.21 | $924.78K | 0 |
| Barrett Katz Chief Medical Officer | Jan 17, 2023 | Option exercise | +24,853 | $23.03 | $572.36K | 24,853 |
| Barrett Katz Chief Medical Officer | Jan 13, 2023 | Sale(10b5-1 plan) | −4,147 | $37.01 | $153.48K | 0 |
| Barrett Katz Chief Medical Officer | Jan 13, 2023 | Option exercise | +4,147 | $23.03 | $95.51K | 4,147 |
| Barrett Katz Chief Medical Officer | Jan 10, 2023 | Sale(10b5-1 plan) | −47,377 | $35.30 | $1.67M | 0 |
| Barrett Katz Chief Medical Officer | Jan 10, 2023 | Option exercise | +47,377 | $23.03 | $1.09M | 47,377 |
| Barrett Katz Chief Medical Officer | Jan 9, 2023 | Sale(10b5-1 plan) | −12,623 | $33.04 | $417.06K | 0 |
| Barrett Katz Chief Medical Officer | Jan 9, 2023 | Option exercise | +12,623 | $23.03 | $290.71K | 12,623 |
| Lara Meisner General Counsel and Secretary | Dec 21, 2022 | Sale(10b5-1 plan) | −16,326 | $29.19 | $476.56K | 0 |
| Lara Meisner General Counsel and Secretary | Dec 21, 2022 | Option exercise | +16,326 | $23.03 | $375.99K | 16,326 |
| Lara Meisner General Counsel and Secretary | Dec 20, 2022 | Sale(10b5-1 plan) | −600 | $28.07 | $16.84K | 0 |
| Lara Meisner General Counsel and Secretary | Dec 20, 2022 | Option exercise | +600 | $23.03 | $13.82K | 600 |
| Lara Meisner General Counsel and Secretary | Dec 16, 2022 | Sale(10b5-1 plan) | −1,297 | $28.44 | $36.89K | 0 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Viridian Therapeutics, Inc.\DE's stock actually held short. Settlement fails (shares not delivered on time) peaked at 51,630 shares on Sep 22, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Jennifer Tousignant Officer | Aug 19, 2026 | 14,212 | $348.19K | Aug 19, 2026 | Restricted Stock Vesting |
| Thomas W. Beetham Officer | Mar 4, 2026 | 3,048 | $92.00K | Mar 4, 2026 | Restricted Stock Vesting |
| Seth Harmon Officer | Mar 4, 2026 | 2,031 | $61.31K | Mar 4, 2026 | Restricted Stock Vesting |
| Jennifer Tousignant Officer | Mar 4, 2026 | 1,675 | $50.56K | Mar 4, 2026 | Restricted Stock Vesting |
| Stephen F. Mahoney Officer, Director | Mar 4, 2026 | 7,408 | $223.61K | Mar 4, 2026 | Restricted Stock Vesting |
| Jennifer Tousignant Officer | Dec 31, 2025 | 2,272 | $70.80K | Dec 31, 2025 | ESPP Purchase |
| Meisner Lara Former Officer | Dec 18, 2023 | 9,375 | $198.38K | Dec 18, 2023 | Option Granted 02/02/2022 |
| Humer Kristian Former CFO | Dec 12, 2023 | 252,600 | $4.33M | Dec 12, 2023 | Option Granted - 07/26/2021 |
| Humer Kristian Former Officer | Dec 7, 2023 | 24,900 | $470.86K | Dec 7, 2023 | Option Granted - 07/26/2021 |
| Meisner Lara Former Officer | Dec 1, 2023 | 3,125 | $53.03K | Dec 1, 2023 | Option Granted 09/22/2021 |
| Myers Scott Dunseth Former Officer and Director | Nov 16, 2023 | 35,368 | $535.12K | Nov 16, 2023 | Restricted Stock Vesting |
| Meisner Lara Officer | Jun 2, 2023 | 12,469 | $305.49K | Jun 2, 2023 | Stock Option Grant |
See a number that looks wrong?